Objective: to determine the rate of NCC in hospital practice at the University Teaching Hospital of Kara and more specifically the socio-demographic characteristics, the different clinical and CT aspects of this affection as well as the evolutionary profile undergoing treatment. Method: a cross-sectional study was conducted at the University Teaching Hospital of Kara from January 1, 2018, to December 31, 2022. Outpatients and inpatients who showed brain imaging signs of NCC were included in this study. Results: Forty-one (41) patients have been included, corresponding to an inpatient frequency of 0.72%. The patient mean age was 49.24 years (SD, 18.67 years) and 26 (63.41%) patients were male. Thirty-one (75.61%) patients presented with epileptic seizures and 15 (36.59%) patients reported headache. Calcification lesions were identified on 36 (87.80%) CT and cystic lesions were visualized on 14 (34.15%) CT. Ischemic stroke lesions were found on the CT scans of 5 (12.20%) patients. Praziquantel was the specific anti-parasitic drug used associated to corticosteroid to minimize inflammatory response. Improvement of the mains symptoms such as seizure and headaches were observed at the end of treatment. Conclusion: NCC is a real public health problem due to the polymorphism of symptoms and clinical signs, making its diagnosis difficult. From this study, mass screening of the population should be carried out, followed by sensitization of all segments of the population, from pig farmers to consumers.
Published in | Clinical Neurology and Neuroscience (Volume 7, Issue 2) |
DOI | 10.11648/j.cnn.20230702.12 |
Page(s) | 31-37 |
Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
Copyright |
Copyright © The Author(s), 2023. Published by Science Publishing Group |
Neurocysticercosis, Epidemiology, Kara University Hospital, Togo, Sub-Saharan Africa
[1] | Del Brutto OH. Neurocysticercosis: A Review. Sci World J 2012; 2012: 1–8. |
[2] | White AC, Coyle CM, Rajshekhar V, et al. Diagnosis and Treatment of Neurocysticercosis: 2017 Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis 2018; 66: 49–75. |
[3] | Garcia HH, Nash TE, Del Brutto OH. Clinical symptoms, diagnosis, and treatment of neurocysticercosis. Lancet Neurol 2014; 13: 1202–1215. |
[4] | Flisser A. State of the Art of Taenia solium as Compared to Taenia asiatica. Korean J Parasitol 2013; 51: 43–49. |
[5] | Flisser A. Taeniasis and cysticercosis due to Taenia solium. Prog Clin Parasitol 1994; 4: 77–116. |
[6] | Mendlovic F, Garza-Rodríguez A, Carrillo-Farga J, et al. From stillness to motion: 80 years after the first description of Taenia solium oncosphere hatching. Parasit Vectors 2014; 7: 12. |
[7] | White AC, Baig S, Robinson P. Taenia saginata oncosphere excretory/secretory peptidases. J Parasitol 1996; 82: 7–10. |
[8] | Kean BH, Mott KE, Russell AJ. Tropical medicine and parasitology: classic investigations. Ithaca, N. Y.: Cornell University Press, 1978. |
[9] | Praet N, Speybroeck N, Manzanedo R, et al. The Disease Burden of Taenia solium Cysticercosis in Cameroon. PLoS Negl Trop Dis 2009; 3: e406. |
[10] | Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet Lond Engl 2015; 386: 743–800. |
[11] | Marcin Sierra M, Arroyo M, Cadena Torres M, et al. Extraparenchymal neurocysticercosis: Demographic, clinicoradiological, and inflammatory features. PLoS Negl Trop Dis 2017; 11: e0005646. |
[12] | Del Brutto OH. Neurocysticercosis. Handb Clin Neurol 2014; 121: 1445–1459. |
[13] | Del Brutto OH. Twenty-five years of evolution of standard diagnostic criteria for neurocysticercosis. How have they impacted diagnosis and patient outcomes? Expert Rev Neurother 2020; 20: 147–155. |
[14] | Del Brutto OH. Current approaches to cysticidal drug therapy for neurocysticercosis. Expert Rev Anti Infect Ther 2020; 18: 789–798. |
[15] | Carabin H, Ndimubanzi PC, Budke CM, et al. Clinical manifestations associated with neurocysticercosis: a systematic review. PLoS Negl Trop Dis 2011; 5: e1152. |
[16] | Brutto OHD, Nash TE, White AC, et al. Revised diagnostic criteria for neurocysticercosis. J Neurol Sci 2017; 372: 202–210. |
[17] | Guzman C, Garcia HH. Current Diagnostic Criteria for Neurocysticercosis. Res Rep Trop Med 2021; Volume 12: 197–203. |
[18] | Dumas M, Grunitzky K, Belo M, et al. [Cysticercosis and neurocysticercosis: epidemiological survey in North Togo]. Bull Soc Pathol Exot 1990 1990; 83: 263–274. |
[19] | Avode DG. Épidémiologie de la neurocysticercose en Afrique Noire. Médecine Afr Noire 1996; 468–71. |
[20] | Balogou AAK, Grunitzky KE, Beketi KA, et al. Cysticercose et épilepsie au nord du Togo dans le Tone. Cysticercose Épilepsie Au Nord Togo Dans Tone 2000; 156: 270–273. |
[21] | Melki J, Koffi E, Boka M, et al. Taenia solium cysticercosis in West Africa: status update. Parasite; 25: 49. |
[22] | Son H-J, Kim MJ, Jung KH, et al. Neurocysticercosis: Clinical Characteristics and Changes from 26 Years of Experience in an University Hospital in Korea. Korean J Parasitol 2019; 57: 265–271. |
[23] | Bazan R, Hamamoto Filho PT, Luvizutto GJ, et al. Clinical Symptoms, Imaging Features and Cyst Distribution in the Cerebrospinal Fluid Compartments in Patients with Extraparenchymal Neurocysticercosis. PLoS Negl Trop Dis 2016; 10: e0005115. |
[24] | Khairuzzaman M, Chowdhury FM, Zaman S, et al. Food Safety Challenges towards Safe, Healthy, and Nutritious Street Foods in Bangladesh. Int J Food Sci 2014; 2014: e483519. |
[25] | Bryan FL. Risks of practices, procedures and processes that lead to outbreaks of foodborne diseases. J Food Prot 1988; 51: 663–673. |
[26] | Mosupye FM, von Holy A. Microbiological hazard identification and exposure assessment of street food vending in Johannesburg, South Africa. Int J Food Microbiol 2000; 61: 137–145. |
[27] | Rajshekhar V. Severe episodic headache as the sole presenting ictal event in patients with a solitary cysticercus granuloma. Acta Neurol Scand 2000; 102: 44–46. |
[28] | Del Brutto OH, Del Brutto VJ. Calcified neurocysticercosis among patients with primary headache. Cephalalgia Int J Headache 2012; 32: 250–254. |
[29] | Fleury A, Carrillo-Mezo R, Flisser A, et al. Subarachnoid basal neurocysticercosis: a focus on the most severe form of the disease. Expert Rev Anti Infect Ther 2011; 9: 123–133. |
[30] | Callacondo D, Garcia HH, Gonzales I, et al. High frequency of spinal involvement in patients with basal subarachnoid neurocysticercosis. Neurology 2012; 78: 1394–1400. |
[31] | Gripper LB, Welburn SC. Neurocysticercosis infection and disease–A review. Acta Trop 2017; 166: 218–224. |
[32] | Del Brutto OH, Wadia NH, Dumas M, et al. Proposal of diagnostic criteria for human cysticercosis and neurocysticercosis. J Neurol Sci 1996; 142: 1–6. |
[33] | Wang W. Combined antiparasitic treatment for neurocysticercosis. Lancet Infect Dis 2015; 15: 265–266. |
[34] | Butala C, Brook TM, Majekodunmi AO, et al. Neurocysticercosis: Current Perspectives on Diagnosis and Management. Front Vet Sci 2021; 8: 615703. |
[35] | Garcia HH, Gonzales I, Lescano AG, et al. Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial. Lancet Infect Dis 2014; 14: 687–695. |
[36] | Garcia HH, Del Brutto OH, Cysticercosis Working Group in Peru. Antiparasitic treatment of neurocysticercosis-The effect of cyst destruction in seizure evolution. Epilepsy Behav EB 2017; 76: 158–162. |
[37] | Hobbs EC, Mwape KE, Phiri AM, et al. Perceptions and acceptability of piloted Taenia solium control and elimination interventions in two endemic communities in eastern Zambia. Transbound Emerg Dis 2020; 67 Suppl 2: 69–81. |
APA Style
Léhleng Agba, Lihanimpo Djalogue, Abide Talabewi, Nyinèvi Komla Anayo, Kokou Mensah Guinhouya, et al. (2023). Neurocysticercosis at UTH of Kara: Epidemiological, Clinical, Diagnostic, Therapeutic and Evolutive Aspects. Clinical Neurology and Neuroscience, 7(2), 31-37. https://doi.org/10.11648/j.cnn.20230702.12
ACS Style
Léhleng Agba; Lihanimpo Djalogue; Abide Talabewi; Nyinèvi Komla Anayo; Kokou Mensah Guinhouya, et al. Neurocysticercosis at UTH of Kara: Epidemiological, Clinical, Diagnostic, Therapeutic and Evolutive Aspects. Clin. Neurol. Neurosci. 2023, 7(2), 31-37. doi: 10.11648/j.cnn.20230702.12
AMA Style
Léhleng Agba, Lihanimpo Djalogue, Abide Talabewi, Nyinèvi Komla Anayo, Kokou Mensah Guinhouya, et al. Neurocysticercosis at UTH of Kara: Epidemiological, Clinical, Diagnostic, Therapeutic and Evolutive Aspects. Clin Neurol Neurosci. 2023;7(2):31-37. doi: 10.11648/j.cnn.20230702.12
@article{10.11648/j.cnn.20230702.12, author = {Léhleng Agba and Lihanimpo Djalogue and Abide Talabewi and Nyinèvi Komla Anayo and Kokou Mensah Guinhouya and Massaga Dagbe and Adama Mawuliplimi Ephoevi-Ga and Vinyo Kumako and Damelan Kombate and Komi Assogba and Agnon Ayolola Balogou}, title = {Neurocysticercosis at UTH of Kara: Epidemiological, Clinical, Diagnostic, Therapeutic and Evolutive Aspects}, journal = {Clinical Neurology and Neuroscience}, volume = {7}, number = {2}, pages = {31-37}, doi = {10.11648/j.cnn.20230702.12}, url = {https://doi.org/10.11648/j.cnn.20230702.12}, eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.cnn.20230702.12}, abstract = {Objective: to determine the rate of NCC in hospital practice at the University Teaching Hospital of Kara and more specifically the socio-demographic characteristics, the different clinical and CT aspects of this affection as well as the evolutionary profile undergoing treatment. Method: a cross-sectional study was conducted at the University Teaching Hospital of Kara from January 1, 2018, to December 31, 2022. Outpatients and inpatients who showed brain imaging signs of NCC were included in this study. Results: Forty-one (41) patients have been included, corresponding to an inpatient frequency of 0.72%. The patient mean age was 49.24 years (SD, 18.67 years) and 26 (63.41%) patients were male. Thirty-one (75.61%) patients presented with epileptic seizures and 15 (36.59%) patients reported headache. Calcification lesions were identified on 36 (87.80%) CT and cystic lesions were visualized on 14 (34.15%) CT. Ischemic stroke lesions were found on the CT scans of 5 (12.20%) patients. Praziquantel was the specific anti-parasitic drug used associated to corticosteroid to minimize inflammatory response. Improvement of the mains symptoms such as seizure and headaches were observed at the end of treatment. Conclusion: NCC is a real public health problem due to the polymorphism of symptoms and clinical signs, making its diagnosis difficult. From this study, mass screening of the population should be carried out, followed by sensitization of all segments of the population, from pig farmers to consumers.}, year = {2023} }
TY - JOUR T1 - Neurocysticercosis at UTH of Kara: Epidemiological, Clinical, Diagnostic, Therapeutic and Evolutive Aspects AU - Léhleng Agba AU - Lihanimpo Djalogue AU - Abide Talabewi AU - Nyinèvi Komla Anayo AU - Kokou Mensah Guinhouya AU - Massaga Dagbe AU - Adama Mawuliplimi Ephoevi-Ga AU - Vinyo Kumako AU - Damelan Kombate AU - Komi Assogba AU - Agnon Ayolola Balogou Y1 - 2023/07/08 PY - 2023 N1 - https://doi.org/10.11648/j.cnn.20230702.12 DO - 10.11648/j.cnn.20230702.12 T2 - Clinical Neurology and Neuroscience JF - Clinical Neurology and Neuroscience JO - Clinical Neurology and Neuroscience SP - 31 EP - 37 PB - Science Publishing Group SN - 2578-8930 UR - https://doi.org/10.11648/j.cnn.20230702.12 AB - Objective: to determine the rate of NCC in hospital practice at the University Teaching Hospital of Kara and more specifically the socio-demographic characteristics, the different clinical and CT aspects of this affection as well as the evolutionary profile undergoing treatment. Method: a cross-sectional study was conducted at the University Teaching Hospital of Kara from January 1, 2018, to December 31, 2022. Outpatients and inpatients who showed brain imaging signs of NCC were included in this study. Results: Forty-one (41) patients have been included, corresponding to an inpatient frequency of 0.72%. The patient mean age was 49.24 years (SD, 18.67 years) and 26 (63.41%) patients were male. Thirty-one (75.61%) patients presented with epileptic seizures and 15 (36.59%) patients reported headache. Calcification lesions were identified on 36 (87.80%) CT and cystic lesions were visualized on 14 (34.15%) CT. Ischemic stroke lesions were found on the CT scans of 5 (12.20%) patients. Praziquantel was the specific anti-parasitic drug used associated to corticosteroid to minimize inflammatory response. Improvement of the mains symptoms such as seizure and headaches were observed at the end of treatment. Conclusion: NCC is a real public health problem due to the polymorphism of symptoms and clinical signs, making its diagnosis difficult. From this study, mass screening of the population should be carried out, followed by sensitization of all segments of the population, from pig farmers to consumers. VL - 7 IS - 2 ER -